In their paper published in the journal Pediatrics, Massachusetts General Hospital (MGH) investigators Shane Shucheng Wong, MD, and Timothy Wilens, MD - both of the MGH Department of Psychiatry - report that their review suggests only two pediatric uses of medical cannabis - to relieve chemotherapy-induced nausea and vomiting and to reduce seizures - are supported by existing studies.
The researchers followed established procedures in searching for studies of medical cannabis use listed in major research indexes and selected out those that primarily enrolled participants aged 18 and under and included original data about a clinical use. Only 21 papers reporting on a total of 22 studies met their criteria. The papers were published from 1979 to 2017, 14 within the last five years. Only 5 were randomized controlled trials, the others being case reports, open-label trials, parent surveys or case series. The most common conditions studied were chemotherapy-induced nausea and vomiting (6 studies) and seizures (11 studies).
The trials for chemotherapy side effects - 4 of which were randomized controlled trials - found that medical cannabis was significantly better than anti-nausea drugs standard at the time of study for reducing nausea and vomiting. Similarly the epilepsy studies, including a single randomized trial, found that medical cannabis reduced the frequency of seizures in participants, some with treatment-resistant seizures. Limitations of these studies include lack of a control group for many, small sample size, differences in the medications used and lack of long-term follow-up.
“Medical cannabis is now legal in 29 states and the District of Columbia, and in those areas with active programs, children and adolescents can legally access medical cannabis with certification from their doctor and consent from a parent or guardian,” says lead author Wong. “This means that doctors and families need to understand what we know and what we don’t yet know about medical cannabis in order to make the best decision for the health of the individual child.”
Two synthetic cannabinoids – compounds that act on specific receptors in the brain – have been approved for medical use in the U.S., both of which mimic a form of THC (tetrahydrocannabinol), the compound responsible for the “high” of recreational cannabis use. Dronabinol (Marinol) is approved to treat chemotherapy-induced nausea and vomiting in both children and adults, while the pediatric use of nabilone (Cesamet) carries a caution. A third cannabinoid, cannabidiol, is currently in phase 3 trials for treatment of seizures.
9:00 am - 1:00 pm
3:00 pm - 7:00 pm
9:00 am - 12:30 pm
2:30 pm - 5:00 pm
9:00 am - 1:00 pm
2:30 pm - 6:00 pm
9:00 am - 1:00 pm
2:30 pm - 6:00 pm
9:00 am - 1:00 pm
2:30 pm - 5:00 pm
By APPT
Only
Closed
9:00 am - 1:00 pm
3:00 pm - 7:00 pm
9:00 am - 12:30 pm
3:00 pm - 7:00 pm
9:00 am - 1:00 pm
3:00 pm - 7:00 pm
Out
3:00 pm - 7:00 pm
9:00 am - 1:00 pm
3:00 pm - 5:00 pm
By Appt
Only
Closed
9:00 am - 6:00 pm
9:00 am - 6:00 pm
9:00 am - 6:00 pm
9:00 am - 6:00 pm
9:00 am - 6:00 pm
By Appt
By Appt
Closed
9010 R G Skinner Pkwy
Jacksonville, FL 32256, US